These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 25956796)

  • 1. Pazopanib: a new drug for pancreatic neuroendocrine tumours.
    Kwekkeboom DJ
    Lancet Oncol; 2015 Jun; 16(6):606-7. PubMed ID: 25956796
    [No Abstract]   [Full Text] [Related]  

  • 2. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study.
    Phan AT; Halperin DM; Chan JA; Fogelman DR; Hess KR; Malinowski P; Regan E; Ng CS; Yao JC; Kulke MH
    Lancet Oncol; 2015 Jun; 16(6):695-703. PubMed ID: 25956795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of chemotherapy in the management of neuroendocrine tumors.
    Oberg K
    Endocrinol Metab Clin North Am; 1993 Dec; 22(4):941-52. PubMed ID: 8125079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of sunitinib in patients with advanced neuroendocrine tumors.
    Kulke MH; Lenz HJ; Meropol NJ; Posey J; Ryan DP; Picus J; Bergsland E; Stuart K; Tye L; Huang X; Li JZ; Baum CM; Fuchs CS
    J Clin Oncol; 2008 Jul; 26(20):3403-10. PubMed ID: 18612155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chemotherapy of digestive neuroendocrine tumors].
    Rougier P; Toma C; Fabri MC; Ducreux M
    Ann Gastroenterol Hepatol (Paris); 1995; 31(2):117-20. PubMed ID: 7618833
    [No Abstract]   [Full Text] [Related]  

  • 6. [Neuroendocrine tumors of the pancreas].
    Gorgone A; Calbo L; Melita G; Riso F; Tigano D; Barbuscia M
    Chir Ital; 1999; 51(4):309-12. PubMed ID: 10633841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surufatinib: First Approval.
    Syed YY
    Drugs; 2021 Apr; 81(6):727-732. PubMed ID: 33788183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors.
    Castellano D; Grande E; Valle J; Capdevila J; Reidy-Lagunes D; O'Connor JM; Raymond E
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1099-114. PubMed ID: 25480314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose administration of oral pazopanib for the treatment of recurrent angiosarcoma.
    Miura H; Shirai H
    Clin Exp Dermatol; 2015 Jul; 40(5):575-7. PubMed ID: 25753734
    [No Abstract]   [Full Text] [Related]  

  • 10. Systemic chemotherapy of advanced digestive neuroendocrine tumours.
    Rougier P; Ducreux M
    Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S202-6. PubMed ID: 10604131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.
    Kulke MH; Stuart K; Enzinger PC; Ryan DP; Clark JW; Muzikansky A; Vincitore M; Michelini A; Fuchs CS
    J Clin Oncol; 2006 Jan; 24(3):401-6. PubMed ID: 16421420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce Durable Response.
    Gupta VG; Rangaraju RR; Saha R; Bajpai P
    J Gastrointest Cancer; 2019 Dec; 50(4):943-946. PubMed ID: 29961919
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors.
    Shah MH; Young D; Kindler HL; Webb I; Kleiber B; Wright J; Grever M
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6111-8. PubMed ID: 15447997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination analyses of anti-cancer drugs on human neuroendocrine tumor cell lines.
    Larsson DE; Hassan S; Larsson R; Oberg K; Granberg D
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):5-12. PubMed ID: 19381631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroendocrine tumours.
    Granberg D; Oberg K
    Cancer Chemother Biol Response Modif; 2005; 22():471-83. PubMed ID: 16110625
    [No Abstract]   [Full Text] [Related]  

  • 16. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
    Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
    Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promising management of pazopanib-induced liver toxicity.
    Vlenterie M; van Erp NP; van der Graaf WT
    Acta Oncol; 2015 Jul; 54(7):1064-6. PubMed ID: 25734660
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeting the microenvironment in ovarian cancer.
    Lheureux S; Oza AM
    Lancet Oncol; 2015 May; 16(5):485-6. PubMed ID: 25882985
    [No Abstract]   [Full Text] [Related]  

  • 19. Prevention of tumor progression in Stewart-Treves syndrome with a low dose of pazopanib.
    Yamada M; Osada SI; Toyoshima A; Yamada K; Hasunuma N; Manabe M
    J Dermatol; 2019 Jul; 46(7):e263-e265. PubMed ID: 30802322
    [No Abstract]   [Full Text] [Related]  

  • 20. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
    Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T
    Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.